Replies to post #221 on Santarus Inc (SNTS)

[surf1944]

7:02AM Santarus announces commercial launch of UCERIS (budesonide) extended release tablets (SNTS) 13.38 : UCERIS was developed in collaboration with Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. Upon first commercial sale of UCERIS, $7 mln is payable to Cosmo in cash or Santarus common stock, at Cosmo's option.